These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice]. Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916 [TBL] [Abstract][Full Text] [Related]
4. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065 [TBL] [Abstract][Full Text] [Related]
6. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Chiarle R; Simmons WJ; Cai H; Dhall G; Zamo A; Raz R; Karras JG; Levy DE; Inghirami G Nat Med; 2005 Jun; 11(6):623-9. PubMed ID: 15895073 [TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821 [TBL] [Abstract][Full Text] [Related]
9. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999 [TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918 [TBL] [Abstract][Full Text] [Related]
11. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786 [TBL] [Abstract][Full Text] [Related]
14. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651 [TBL] [Abstract][Full Text] [Related]
15. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868 [TBL] [Abstract][Full Text] [Related]